International Business News - IMCL http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Goldman Sachs and Co. downgraded ImClone Systems Inc. stock to "neutral" with a price target of $64 per share, near its current trading price. ImClone shares closed at $63.97 on Thursday. http://www.ibtimes.com/articles/20080905/goldman-sachs-downgrades-imclone-on-valuation.htm Fri, 05 Sep 2008 09:30:36 EDT ImClone Systems Inc. said Wednesday it has asked regulators to approve its drug Erbitux as a primary treatment for head and neck cancers. New York-based ImClone, which partners with Bristol-Myers Squibb Co. to market the drug, said it asked the Food and Drug Administration to expand the Erbitux label to include recurrent or metastasized squamous cell carcimona of the head and neck, in combination with chemotherapy. The companies requested a priority review, hoping the FDA will approve the new label within six months. http://www.ibtimes.com/articles/20080903/imclone-requests-expanded-erbitux-label.htm Wed, 03 Sep 2008 16:01:48 EDT Shares of Bristol-Myers Squibb Co. dipped Wednesday after the drug developer said its developing blood thinner apixaban failed in a late-stage study. The stock fell 46 cents, or 2.1 percent, to $21.52. Shares have traded between $19.43 and $30.35 over the last 52 weeks. http://www.ibtimes.com/articles/20080827/bristol-myers-shares-dip-on-failed-drug-study.htm Wed, 27 Aug 2008 17:18:43 EDT King Pharmaceuticals Inc. said Friday that rival Alpharma Inc. has rejected a $1.4 billion buyout offer but indicated it is prepared to take the bid directly to shareholders in a move to expand its product offerings. http://www.ibtimes.com/articles/20080822/king-offers-1-4-billion-in-cash-for-alpharma.htm Fri, 22 Aug 2008 16:41:04 EDT A buyout bull's-eye will likely remain on biotechnology companies over the next few years as major pharmaceutical companies continue taking advantage of a weak dollar and a surplus of cash to buy pipeline additions. http://www.ibtimes.com/articles/20080820/biotech-buyout-action-likely-to-continue.htm Wed, 20 Aug 2008 11:41:33 EDT PDL BioPharma Inc.'s stock gained ground Wednesday after pharma giant Bristol-Myers Squibb Co. signed a deal to license the biotechnology company's developing blood cancer drug. http://www.ibtimes.com/articles/20080820/pdl-biopharma-shares-rise-on-licensing-deal.htm Wed, 20 Aug 2008 17:54:33 EDT Rising prices stifle impact of stimulus payments WASHINGTON (AP)--Consumer spending, after adjusting for inflation, fell in June as shoppers were hit with the second biggest increase in prices in nearly three decades. http://www.ibtimes.com/articles/20080804/business-highlights.htm Mon, 04 Aug 2008 18:24:10 EDT ImClone Systems Inc.'s board of directors said Monday cancer drug partner Bristol-Myers Squibb Co.'s $4.5 billion buyout offer "substantially undervalues" the company, with Chairman Carl Icahn personally against the deal. http://www.ibtimes.com/articles/20080804/imclone-hints-at-dim-view-of-bristol-myers-offer.htm Mon, 04 Aug 2008 17:20:45 EDT Drugmaker Bristol-Myers Squibb Co. said Friday it has completed the sale of its high-tech dressing and wound-care business, which will free up money needed to buy the company's cancer drug partner, ImClone Systems Inc. http://www.ibtimes.com/articles/20080801/bristol-myers-sells-convatec-wound-care-unit.htm Fri, 01 Aug 2008 18:43:40 EDT Rebates helped economy--some--in second quarter WASHINGTON (AP)--The prospects for a quick economic recovery dimmed Thursday, with new data showing the economy grew at a slower-than-expected rate this spring despite some oomph from tax rebate checks--and actually shrank late last year. http://www.ibtimes.com/articles/20080731/business-highlights.htm Thu, 31 Jul 2008 18:36:51 EDT Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and Nasdaq Stock Market: NYSE http://www.ibtimes.com/articles/20080731/imclone-exxon-mobil-motorola-kodak-big-movers.htm Thu, 31 Jul 2008 17:06:04 EDT Bristol-Myers Squibb Co. on Thursday offered $4.5 billion in cash for its cancer drug partner, biotechnology company ImClone Systems Inc., saying the two are "a natural fit." http://www.ibtimes.com/articles/20080731/bristol-myers-offering-4-5-billion-for-imclone.htm Thu, 31 Jul 2008 17:36:27 EDT Wall Street sank Thursday, after weak readings on economic growth and the job market touched off renewed concerns about the financial health of businesses and consumers. The Dow Jones industrial average fell more than 200 points. http://www.ibtimes.com/data/articleimgs/101222-wall-street.jpg http://www.ibtimes.com/articles/20080731/stocks-head-for-lower-open-ahead-of-gdp-reading.htm http://www.ibtimes.com/articles/20080731/stocks-head-for-lower-open-ahead-of-gdp-reading.htm Thu, 31 Jul 2008 17:55:18 EDT Wall Street has so far dealt with a mixed second-quarter report card for biotechnology companies, but shares continue outpacing the broader market on a mix of positive sales results and a bright outlook for buyout potential within the sector. http://www.ibtimes.com/articles/20080724/sector-snap-biotech-outpaces-the-market.htm Thu, 24 Jul 2008 12:49:12 EDT Biotechnology company ImClone Systems Inc. said Thursday its second-quarter profit fell 20.7 percent as rising research and development costs offset royalties and other payments from its only marketed drug, Erbitux. http://www.ibtimes.com/articles/20080724/imclone-2q-profit-dips-on-higher-costs.htm Thu, 24 Jul 2008 10:24:58 EDT Shares throughout the biotechnology sector advanced Monday as Swiss pharmaceutical giant Roche offered to buy Genentech Inc. in potentially the biggest pharma-biotech deal of the year. http://www.ibtimes.com/articles/20080721/sector-snap-biotech-stocks-rise-on-buyout-offer.htm Mon, 21 Jul 2008 11:42:39 EDT Among the stock activity stories for Wednesday, July 16, from AP Financial News: NEW YORK (AP)_ Shares of ImClone Systems Inc. rose Wednesday after the biotechnology company said Japanese regulators approved Erbitux as an advanced colon cancer treatment. http://www.ibtimes.com/articles/20080716/movers-roundup-imclone-usana-health-sciences.htm Wed, 16 Jul 2008 15:11:11 EDT Shares of ImClone Systems Inc. rose Wednesday after the biotechnology company said Japanese regulators approved Erbitux as an advanced colon cancer treatment. http://www.ibtimes.com/articles/20080716/imclone-shares-rise-on-erbitux-approval-in-japan.htm Wed, 16 Jul 2008 19:27:55 EDT Genentech Inc. on Monday reports earnings for its second quarter. The following is a summary of key developments and analyst opinion related to the period. http://www.ibtimes.com/articles/20080711/earnings-preview-genentech.htm Fri, 11 Jul 2008 12:54:22 EDT Shares of OSI Pharmaceuticals Inc. rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an "Overweight" rating, citing accelerating sales of the cancer drug Tarceva. http://www.ibtimes.com/articles/20080627/osi-shares-rise-on-weisel-overweight-rating.htm Fri, 27 Jun 2008 12:09:40 EDT